Molecular and clinical oncology最新文献

{"title":"Low-grade serous ovarian cancer in Indonesia: Insights from the largest multicenter cohort in a middle-income country.","authors":"Brahmana Askandar Tjokroprawiro, Khoirunnisa Novitasari, Wita Saraswati, Renata Alya Ulhaq, Hanif Ardiansyah Sulistya, Syahrul Rauf, Febia Erfiandi, Kade Yudi Saspriyana, Teuku Mirza Iskandar, Very Great Eka Putra, Tofan Widya Utami, Tricia Dewi Anggraeni, Setyo Teguh Waluyo, Henny M A R Putri, Eccita Rahestyningtyas","doi":"10.3892/mco.2026.2963","DOIUrl":"10.3892/mco.2026.2963","url":null,"abstract":"<p><p>Low-grade serous ovarian cancer (LGSOC), a rare subtype of epithelial ovarian cancer, is characterized by indolent growth and limited chemosensitivity. However, data from low- and middle-income countries are limited. The present study aimed to describe the clinical and pathological characteristics of patients with LGSOC in Indonesia. This retrospective multicenter study was conducted at nine tertiary cancer centers across seven provinces, and included patients with histologically confirmed LGSOC diagnosed according to the 2020 World Health Organization Classification of Female Genital Tumors between January 2019 and December 2024. Demographic, clinical, surgical, pathological and treatment data were extracted from medical records. Recurrence was classified as early (<6 months) or late (≥6 months) after completion of primary treatment. Associations between clinicopathological variables and outcomes were analyzed using Fisher's exact test. Kaplan-Meier (KM) survival analysis with log-rank testing and Cox proportional hazards regression were performed, with a restricted multivariate model to minimize overfitting due to limited events. A total of 160 patients (median age, 46 years; range, 17-75 years) were included, with a median follow-up of 24 months. Of the cohort, ~50% presented with advanced-stage disease (International Federation of Gynecology and Obstetrics III-IV, 50%). Ascites and elevated cancer antigen-125 levels were observed in 43.1 and 70.6% of patients, respectively. Primary debulking surgery was performed in 90% of cases, achieving optimal cytoreduction in 72.5%. The overall recurrence rate was 10, and 92.5% of patients were alive at the last follow-up. KM analysis showed worse survival in patients with advanced-stage disease and residual disease. In univariate Cox regression, residual disease (HR, 7.93) and recurrence (HR, 10.06) showed the strongest associations with mortality. In multivariate analysis, only residual disease remained an independent predictor (adjusted HR, 5.59; P=0.013). In this multicenter cohort, residual disease was the key determinant of survival, underscoring the importance of complete cytoreductive surgery and early diagnosis.</p>","PeriodicalId":18737,"journal":{"name":"Molecular and clinical oncology","volume":"25 2","pages":"54"},"PeriodicalIF":1.9,"publicationDate":"2026-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13389679/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148562580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advanced pulmonary carcinoid managed with chemoimmunotherapy and antiangiogenic agent: A case report and literature review.","authors":"Liqiu Sun, Mengying Liu","doi":"10.3892/mco.2026.2962","DOIUrl":"10.3892/mco.2026.2962","url":null,"abstract":"<p><p>Pulmonary carcinoid (PC) tumors are rare, well-differentiated neuroendocrine neoplasms of the lung with indolent progression and limited therapeutic consensus in advanced stages. While surgery remains the mainstay for localized disease, optimal management strategies for progressive or unresectable cases remain debated. A case of a 56-year-old man diagnosed with a left upper lobe PC was presented. Initial treatment consisted of platinum-based chemotherapy followed by traditional Chinese medicine. Upon disease progression, he received thoracic radiotherapy, achieving transient stabilization. However, subsequent radiologic surveillance revealed enlargement of mediastinal lymph nodes, prompting the initiation of a triple-modality systemic regimen comprising lobaplatin, the PD-1 inhibitor sintilimab, and the antiangiogenic agent anlotinib. After two treatment cycles, follow-up imaging demonstrated marked lymph node regression with satisfactory tolerability. This case highlights the potential therapeutic value of integrating chemotherapy, immunotherapy and antiangiogenic therapy in advanced PCs, particularly when standard surgical approaches are unfeasible. Although randomized data remain scarce, experience suggests that multimodal systemic therapy may offer disease control in selected patients. Further prospective studies are warranted to refine treatment paradigms for this uncommon malignancy.</p>","PeriodicalId":18737,"journal":{"name":"Molecular and clinical oncology","volume":"25 2","pages":"53"},"PeriodicalIF":1.9,"publicationDate":"2026-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13365789/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148448090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Occult breast cancer showing a marked response to pembrolizumab plus gemcitabine and carboplatin therapy complicated by immune-related colitis: A case report.","authors":"Wakako Inohana, Masahiro Ohara, Emi Mikami, Taeko Kurosawa, Ayako Nakame, Ayaka Sakakibara, Akihiro Fujimoto, Yuki Ichinose, Asami Nukui, Aya Asano, Hiroko Shimada, Hideki Yokokawa, Yu Miyama, Kazuo Matsuura, Hiroshi Ishiguro, Takahiro Hasebe, Akihiko Osaki, Toshiaki Saeki","doi":"10.3892/mco.2026.2961","DOIUrl":"10.3892/mco.2026.2961","url":null,"abstract":"<p><p>Occult breast cancer (OBC) is a rare condition presenting with axillary or distant lymph node metastases without a detectable primary tumor. Immune checkpoint inhibitors (ICIs) show promise in triple-negative breast cancer (TNBC) treatment; however, their efficacy in OBC remains unclear. The present study describes the case of a 71-year-old woman who presented with left cervical and axillary lymphadenopathy. ¹⁸F-fluorodeoxyglucose positron emission tomography-computed tomography (CT) and breast ultrasonography revealed no detectable primary breast lesion. Core needle biopsy of the axillary lymph node confirmed the diagnosis of TNBC (estrogen receptor, 0%; progesterone receptor, 0%; human epidermal growth factor receptor 2 score, 0). The programmed death-ligand 1 combined positive score was >10. Since the patient had stage IV disease with the biological subtype defined by lymph node biopsy, breast magnetic resonance imaging was not performed to avoid delaying systemic therapy. Pembrolizumab (Pembro) combined with gemcitabine and carboplatin was initiated. However, the patient developed a Grade 1 rash after the first cycle and diarrhea after the second cycle, followed by immune-related colitis requiring hospitalization. Notably, the emergence of immune-related adverse events (irAEs) paralleled a marked treatment response, with non-contrast CT after three cycles showing complete resolution of left axillary lymph node metastases. Pembro was discontinued, and the patient has maintained a complete response on eribulin monotherapy for >1 year. The present case suggests an association between irAEs and the clinical effectiveness of ICIs, highlighting the potential of Pembro-containing chemotherapy for OBC treatment, and emphasizing the importance of prompt irAE recognition and management. Lymph node-dominant disease may represent a particularly immunogenic context for ICI therapy.</p>","PeriodicalId":18737,"journal":{"name":"Molecular and clinical oncology","volume":"25 2","pages":"52"},"PeriodicalIF":1.9,"publicationDate":"2026-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13288626/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148318199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative efficacy and safety of first-line treatments for RAS wild-type metastatic colorectal cancer: A systematic review and network meta-analysis.","authors":"Songke Wu, Chengshi Wang, Shuyun Liu","doi":"10.3892/mco.2026.2960","DOIUrl":"10.3892/mco.2026.2960","url":null,"abstract":"<p><p>Optimal first-line treatments for RAS wild-type metastatic colorectal cancer (mCRC) remain uncertain, despite the availability of numerous targeted therapies. Direct comparisons between all available regimens are limited, necessitating indirect evidence synthesis. A systematic review and network meta-analysis of randomized controlled trials (RCTs) comparing first-line treatments for RAS wild-type mCRC was conducted in the present study. MEDLINE/PubMed, Embase, Cochrane Central Register of Controlled Trials and Web of Science were searched from inception to September 2025. Primary outcomes included overall survival (OS) and progression-free survival (PFS), while secondary outcomes included objective response rate (ORR) and safety profiles. Random-effects network meta-analyses were performed and treatments were ranked using P-scores. In total, 15 RCTs involving 6,298 patients and seven primary treatment nodes were included. The network demonstrated high levels of consistency for OS (I²=0%) and moderate heterogeneity for PFS (I²=44.8%) and ORR (I²=40.9%). For OS, both cetuximab + chemotherapy [hazard ratio (HR)=0.853; 95% CI: 0.775-0.938; P=0.001] and panitumumab + chemotherapy (HR=0.855; 95% CI: 0.738-0.992; P=0.038) exhibited statistically significant superiority compared with bevacizumab + chemotherapy. Cetuximab + chemotherapy ranked highest for OS (P-score=0.814) and PFS (P-score=0.914). Subgroup analysis demonstrated a pronounced tumor sidedness effect. Anti-EGFR therapy provided a 25.0% reduction in OS risk for left-sided tumors (HR=0.750; 95% CI: 0.672-0.836; I²=0%), whereas no survival benefit was observed for right-sided tumors (HR=1.097; 95% CI: 0.909-1.325). Anti-EGFR regimens were associated with higher rates of grade ≥3 toxicities, reaching up to 83.3%, compared with bevacizumab-based regimens, which fell between 23.4-68.3%. In the present sensitivity analysis, UDP glucuronosyltransferase family 1 member A1-guided bevacizumab + 5-fluorouracil, leucovorin and irinotecan demonstrated favorable outcomes, with OS and PFS P-scores of 0.932 and 0.992, respectively; however, these findings were derived from a single trial with limited comparability. Overall, anti-EGFR antibodies combined with chemotherapy demonstrated consistent and statistically significant survival benefits as first-line treatment for RAS wild-type mCRC, with cetuximab + chemotherapy ranking as the optimal regimen. Treatment benefit from anti-EGFR therapy was markedly influenced by primary tumor location, with notable benefit observed in left-sided tumors and no benefit in right-sided tumors. These findings support tumor sidedness-guided treatment selection in clinical practice, favoring anti-EGFR-based therapy for left-sided and bevacizumab-based therapy for right-sided RAS wild-type mCRC.</p>","PeriodicalId":18737,"journal":{"name":"Molecular and clinical oncology","volume":"25 2","pages":"51"},"PeriodicalIF":1.9,"publicationDate":"2026-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13266398/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148265282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Submental artery island flap for reconstruction of lateral oropharyngeal carcinoma in patients with severe anesthesiological risk factors: Functional and oncologic outcomes.","authors":"Sabine Schreiner, Charlotte Maicher, Fabian Kraus, Miguel Goncalves, Stephan Hackenberg, Agmal Scherzad, Thomas Gehrke","doi":"10.3892/mco.2026.2959","DOIUrl":"10.3892/mco.2026.2959","url":null,"abstract":"<p><p>The submental arterial island flap (SMIF) is used mostly for closing defects in the oral cavity, but also has its uses for oropharyngeal reconstruction. Since the duration of surgery is shorter compared with that for free flaps, it appears to be a good option for patients with severe anesthesiological risk factors. Therefore, the present study evaluated the functional and oncological outcomes of reconstructing defects after oropharyngeal carcinoma resection with a SMIF in these patients. A total of 10 patients underwent resection of lateral oropharyngeal carcinoma and ipsilateral neck dissection with closure of the defects using a SMIF. Oncological evaluation consisted of endoscopic and radiological standard-of-care restaging, while functional evaluation included a phoniatric swallowing examination with penetration-aspiration scale-score 6 months after surgery. All patients had T2 or T3 carcinoma, while 7 out of 10 patients had nodal involvement. Additionally, 7 out of 10 patients exhibited p16 expression. Pathological clear margins could be achieved in all patients. In all patients, no local, regional or distant recurrence occurred (median follow-up time, 26 months; range, 12-33 months). All patients had complete oral intake with their feeding tubes removed, with 1 patient restricted to dysphagia diet. Despite the severe comorbidities, there were no surgery-related or anesthesia-related complications. One patient who refused the recommended postoperative radiation developed enoral hair growth requiring regular trimming to avoid dysphagia. The SMIF is a reliable flap for reconstruction of lateral oropharyngeal defects with good oncological and functional outcomes. The reduced anesthesia duration appeared to be beneficial for patients with severe cardiac or pulmonary comorbidities. Male patients should be selected to undergo postoperative radiation to prevent enoral hair growth.</p>","PeriodicalId":18737,"journal":{"name":"Molecular and clinical oncology","volume":"25 1","pages":"50"},"PeriodicalIF":1.9,"publicationDate":"2026-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13237518/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148199502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A transcriptional network underlying migratory cellular states and reduced 5-ALA-based photodynamic detectability in glioblastoma.","authors":"Wenyu Liu, Tingting Zhang, Ichiyo Shibahara, Takuichiro Hide, Toshihiro Kumabe, Shun-Ichiro Ogura, Tetsuya Taga, Kouichi Tabu","doi":"10.3892/mco.2026.2958","DOIUrl":"10.3892/mco.2026.2958","url":null,"abstract":"<p><p>Surgical resection remains the cornerstone of the standard therapy for glioblastoma (GBM), yet postoperative recurrence remains a major clinical challenge. Intraoperative photodynamic detection (PDD) using 5-aminolevulinic acid (5-ALA) improves the precision of tumor removal. However, a subset of tumor cells can evade fluorescence-based detection, potentially contributing to residual disease and relapse. The present study analyzed the relationship between cellular migratory capacity and 5-ALA PDD visibility using six patient-derived GBM cell lines (KBT#12137, KBT#10135, KBT#10170, PDM19, PDM22 and PDM123). This study revealed a positive correlation, indicating that cells with higher migratory potential accumulated lower levels of 5-ALA-induced protoporphyrin IX and were therefore more likely to escape intraoperative detection. Transcriptomic profiling identified gene expression signatures specifically associated with this phenotype, highlighting pathways related to cytoskeletal regulation, heme metabolism, and transporter activity. These findings suggest that the migratory potential and diagnostic evasion are functionally linked through shared molecular programs, thereby providing a potential basis for identifying predictive biomarkers associated with incomplete resection and recurrence risk. Overall, this study provides insights that may contribute to improved intraoperative strategies and targeted therapeutic approaches for GBM.</p>","PeriodicalId":18737,"journal":{"name":"Molecular and clinical oncology","volume":"25 1","pages":"49"},"PeriodicalIF":1.9,"publicationDate":"2026-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13218275/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148138364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Virulence factors of the microbiome: A functional toolkit for cancer progression (Review).","authors":"Kiruthika Vijayakumar, Benedict Christopher Paul","doi":"10.3892/mco.2026.2957","DOIUrl":"10.3892/mco.2026.2957","url":null,"abstract":"<p><p>The paradigm of cancer biology has shifted to recognize tumor as a complex ecosystem inhabited by a diverse microbiome. Beyond mere association, the molecular mechanisms driven by microbial virulence factors are critical for understanding how these microorganisms contribute to malignancy. The present review describes a virulence factor-centric framework to deconstruct the microbial 'toolkit' and illustrate its role in enabling the Hallmarks of Cancer. The major classes of virulence factors were systematically analyzed, detailing how each contributes to tumor progression. It was described how bacterial adhesins (for example, Fusobacterium adhesin A and Fap2) initiate oncogenic signaling and mediate immune evasion; how secreted toxins drive genomic instability (Colibactin and CDT) and corrupt cellular signaling pathways (CagA and <i>Bacteroides fragilis</i> toxin); how degradative enzymes (gingipains and collagenases) dismantle the extracellular matrix to facilitate physical invasion; how viral oncoproteins (Human Papillomavirus E6/E7 and Epstein Barr virus latent membrane protein 1) hijack core cell cycle machinery; and how microbial structural components (lipopolysaccharides and extracellular vesicles) and metabolites (secondary bile acids) sustain a pro-tumorigenic environment. This analysis reveals a pattern of functional convergence, where diverse microbial agents repeatedly target core host pathways such as NF-κB, Wnt/β-catenin and p53. This mechanistic understanding reframes the microbiome as an active orchestrator of malignancy and reveals a new frontier of therapeutic targets. Strategies aimed at neutralizing specific virulence factors or modulating the tumor ecosystem represent a novel and promising pillar in oncology.</p>","PeriodicalId":18737,"journal":{"name":"Molecular and clinical oncology","volume":"25 1","pages":"48"},"PeriodicalIF":1.9,"publicationDate":"2026-05-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13199945/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148032963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Secretory carcinoma in the parotid gland: A case report.","authors":"Misaki Hayashi, Nobuyuki Bandoh, Takashi Goto, Shuto Hayashi, Ryota Arima, Koki Nakamuta, Tomomi Isochi-Yamaguchi, Shogo Baba, Yasutaka Kato, Miki Takahara, Hidehiro Takei","doi":"10.3892/mco.2026.2956","DOIUrl":"10.3892/mco.2026.2956","url":null,"abstract":"<p><p>Secretory carcinoma (SC) is a rare salivary gland neoplasm characterized by the ETV6::NTRK3 gene fusion, and it has been recognized as a distinct entity in the World Health Organization Classification of Head and Neck Tumors since 2017. Case 1 involved a 21-year-old Japanese man who presented with a 1-year history of a slow-growing, painless mass in the right parotid gland. Ultrasonography and magnetic resonance imaging demonstrated a well-circumscribed, homogeneous tumor measuring 16x12x10 mm. The patient underwent superficial parotidectomy. Case 2 involved a 79-year-old Japanese man who noticed a mass in the right parotid region 3 weeks before presentation. Imaging studies revealed a tumor with irregular margins and heterogeneous internal features, measuring 21x16x15 mm. The patient underwent total parotidectomy with selective neck dissection. Histological examination revealed features consistent with SC in both cases. Immunohistochemically, the tumor cells were positive for S-100 protein, mammaglobin and cytokeratin 7. The diagnosis was further supported by detection of the ETV6::NTRK3 gene fusion using reverse transcription-polymerase chain reaction and Sanger sequencing. Both patients received postoperative radiotherapy at a total dose of 60 Gy. No evidence of local recurrence or distant metastasis has been observed during the follow-up period of 7 years in case 1 and 3 years in case 2.</p>","PeriodicalId":18737,"journal":{"name":"Molecular and clinical oncology","volume":"25 1","pages":"47"},"PeriodicalIF":1.9,"publicationDate":"2026-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13200264/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148032884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Icariin: Multi-target natural products for the multi-stage prevention and treatment of breast cancer (Review).","authors":"Yu Wen, Yunyan Chen, Lei Yang, Tingfen Wu, Qinghua Peng, Huiyan Xie, Xuemei Chen","doi":"10.3892/mco.2026.2954","DOIUrl":"10.3892/mco.2026.2954","url":null,"abstract":"<p><p>The present review examines the intricate relationship between icariin and breast cancer (BC), encompassing foundational theoretical concepts, epidemiological data, diagnostic methodologies, therapeutic approaches, ongoing debates and prospective future developments. The foundational theoretical concepts address the mechanisms through which icariin influences BC pathogenesis, as well as its pharmacokinetic and pharmacodynamic properties and historical context. The epidemiological section analyzes the global incidence and prevalence of BC, alongside its underlying pathophysiology. Diagnostic methodologies are discussed with a focus on imaging technologies, biomarkers, and the innovative role of icariin in advancing diagnostic techniques. Therapeutic approaches investigate icariin's potential as a chemo-preventive agent, its synergistic interactions with conventional therapies and the outcomes of clinical trials. The section on controversies explores discussions surrounding icariin's efficacy, safety and the associated regulatory and ethical considerations. Future directions emphasize emerging trends, the potential for personalized medicine, and future prospects in BC treatment. The present review aims to offer a comprehensive understanding of icariin's role in BC research and therapeutic applications.</p>","PeriodicalId":18737,"journal":{"name":"Molecular and clinical oncology","volume":"25 1","pages":"45"},"PeriodicalIF":1.9,"publicationDate":"2026-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13173617/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147963895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Presence of tuft cells expressing haematopoietic prostaglandin D synthase in intraductal papillary mucinous neoplasms of the pancreas.","authors":"Kensuke Nakanishi, Mitsuaki Ishida, Kenta Hosomi, Kohei Taniguchi, Jun Arima, Atsushi Tomioka, Mitsuhiro Asakuma, Yoshiharu Miyamoto, Ko Fujimori, Yoshinobu Hirose, Sang-Woong Lee","doi":"10.3892/mco.2026.2955","DOIUrl":"10.3892/mco.2026.2955","url":null,"abstract":"<p><p>Intraductal papillary mucinous neoplasm (IPMN) is the second most common pancreatic tumour and a common precursor lesion of invasive carcinoma. Tuft cells are chemosensory epithelial cells present in the gastrointestinal and respiratory tracts that serve roles in response to infection and tissue repair. In addition, tuft cells have pivotal roles in the carcinogenesis of pancreatic ductal adenocarcinoma (PDAC), especially in tumour suppression, by producing prostaglandin (PG)D₂; however, their role in IPMN remains unclear. The present study aimed to evaluate the presence of tuft cells producing PGD₂ in human IPMN. Consecutive patients with IPMN who underwent surgical resection were retrospectively enrolled. Dual immunohistochemical staining for POU domain class 2 transcription factor 3 (POU2F3), as a specific tuft cell marker, and haematopoietic PGD synthase (H-PGDS), as a useful marker for PGD₂ production, were performed. The present study included 21 patients with IPMN (11 women and 10 men; median age, 74 years). A total of 11, two and eight patients had IPMN with low-grade dysplasia, high-grade dysplasia and associated invasive carcinoma, respectively. POU2F3-positive tuft cells were noted in IPMN, and 20.0% of POU2F3-positive cells in IPMN without invasive carcinoma and the non-invasive regions of IPMN-associated invasive carcinoma expressed H-PGDS. Moreover, POU2F3-positive tuft cells and the ratio of H-PGDS expression in POU2F3-positive tuft cells were significantly lower in the invasive regions than in the non-invasive regions of IPMN-associated invasive carcinoma. These results indicated that POU2F3-positive tuft cells have possible roles in the tumourigenesis of IPMN, as well as in the carcinogenesis of PDAC, because tuft cells present in non-invasive IPMN may serve tumour-suppressive roles via production of PGD₂ and they were absent in the invasive carcinoma component. Notably, further analyses are required to clarify the role and importance of POU2F3-positive tuft cells in IPMN, which will lead to a better understanding of the pathogenesis of this tumour.</p>","PeriodicalId":18737,"journal":{"name":"Molecular and clinical oncology","volume":"25 1","pages":"46"},"PeriodicalIF":1.9,"publicationDate":"2026-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13172954/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147963874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}